Curis, Inc. (CRIS)
Develops experimental cancer drugs targeting immune pathways and cell signaling.
$4.83+0.03%Healthcare
StockGlow Score
Neutral
BearishBullish
1 year ago-85.2%
The outlook
Curis trades near the lower end of its 52-week range and below both its 50- and 200-day moving averages. The three analysts covering it rate it a Strong Buy with an average price target suggesting substantial upside from current levels. Overall sentiment remains neutral despite the bullish analyst view and the stock's position in its recent trading range.
What’s behind the score
Analyst consensusStrong Buy — 1.3 avg of 3 analysts
Price trendBelow its 50- & 200-day averages
52-week range3% of the way from its 52-week low to high
Price targetAvg target +1335% vs current price
Analyst price target
~12-month · 3 analysts$69.33average target+1335.5% vs now
Now $4.83
Low $43.00High $100.00
Published targets from Wall Street analysts (public data) — what analysts expect over roughly a year. This is not a StockGlow forecast and not a recommendation. Analyst targets are frequently wrong.
Market cap
$9.4M
52-wk high
$39.00
52-wk low
$3.60
50-day avg
$7.67
200-day avg
$17.10
Trailing P/E
—